UNSPSC 51332801: Chlorproethazine

This classification denotes an anticholinergic agent with the molecular formula C19H23ClN2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 960NX27Z07, chemically known as 10h-phenothiazine-3-propanamine, 2-chloro-n,n-diethyl-, monohydrochloride but generally known as chlorproethazine, which bears US NIH Compound Identifier 65750. European Medicines Agency schedules Chlorproethazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06206MIG.

UNSPSC 51332801 Chlorproethazine, a Commodity code, shows no direct alignment with recent state and local procurement activity. The three most recent opportunities posted under or near this code—Seminole County's Naloxone and Safe Drug Deactivation Systems IFB (due July 26, 2023), the Texas HHS Commission's Therapeutic Pharmacy Initiative RFI (due April 3, 2026), and the Minnesota Multistate Cooperative Purchasing Alliance's Generic Multi Source Pharmaceuticals RFP (due March 26, 2026)—involve naloxone, direct-to-manufacturer prescription programs, and broad generic pharmaceuticals and OTC products, none of which match the specific pharmaceutical chlorproethazine. The issuing bodies span county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances serving multiple jurisdictions (MMCAP, Minnesota), indicating that state and local governments do procure pharmaceutical products through a mix of individual and cooperative mechanisms.

The geographic activity centers on Florida, Texas, and Minnesota, with MMCAP's cooperative structure extending to Oregon and other participating jurisdictions. The mismatch between the code's nominal scope and the actual recent solicitations suggests that either chlorproethazine experiences minimal state and local demand or the code is rarely applied to posted opportunities in practice. Absent specific recent procurements for chlorproethazine itself, the code shows limited current traction for business development purposes. Firms pursuing state and local pharmaceutical supply should monitor broader generic-drug and OTC-product cooperatives like MMCAP and track individual county and state health agency RFPs that may address specific therapeutic classes or drug products.